Trial Profile
A Study to Evaluate the Association Between BCR-ABL1 Transcript Levels and Progression Free Survival and Event Free Survival in Chronic Myeloid Leukemia (CML) Patients Treated With Imatinib Who Switched Therapy to Dasatinib or Nilotinib
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 May 2016
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Pharmacodynamics; Therapeutic Use
- 11 May 2016 New trial record